Find insight on Samsung Biologics, China biotech companies and more in the latest Market Talks covering Health Care.

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, for treating bone diseases and related conditions ...

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...

And the journey wasn’t always smooth. McDowell is now the Vice President of Sales at Restorative Biologics, but his story starts in Memphis, Tennessee—where discipline, competition, and family values ...

LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) conjugation services. With over $100 million invested in ADC modalities, including both drug ...

Samsung Biologics is also exploring partnerships with overseas hospitals to broaden its patient-derived organoid bank and is considering future data licensing models. While its organoid unit may start ...

Samsung Biologics has also established sales offices in New Jersey, Boston, and earlier this year in Tokyo, Japan, to expand its CDMO orders. CEO John Lim predicted that the CDMO market will ...

The Securities and Futures Commission later concluded that Samsung Biologics had conducted about 4.5 trillion won worth of accounting fraud, by changing the classification of Samsung Bioepis from ...

Samsung’s Galaxy Watch line offers a variety of health and fitness features, and the company is adding even more via the One UI 8 Watch update. Now, Samsung has confirmed that it’s thinking ...

Last week, Samsung Biologics, the biotech unit of Korea’s top conglomerate Samsung Group, said it will spin off its biosimilar and novel drug development business, undertaken by Samsung Bioepis Co., ...